Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Amortization of Deferred Charges (2023 - 2025)

Compass Therapeutics' Amortization of Deferred Charges history spans 3 years, with the latest figure at -$1.2 million for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 342.96% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached -$1.7 million, down 1.33%, while the annual FY2025 figure was -$1.7 million, 1.33% down from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was -$1.2 million at Compass Therapeutics, down from -$375000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $26000.0 in Q1 2025 and bottomed at -$1.2 million in Q4 2025.
  • The 3-year median for Amortization of Deferred Charges is -$484500.0 (2023), against an average of -$545833.3.
  • The largest YoY upside for Amortization of Deferred Charges was 106.91% in 2025 against a maximum downside of 342.96% in 2025.
  • A 3-year view of Amortization of Deferred Charges shows it stood at -$812000.0 in 2023, then soared by 66.75% to -$270000.0 in 2024, then crashed by 342.96% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Amortization of Deferred Charges are -$1.2 million (Q4 2025), -$375000.0 (Q3 2025), and -$128000.0 (Q2 2025).